Last update Jan. 4, 2020
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Reserpine is also known as
Reserpine in other languages or writings:
Reserpine belongs to this group or family:
Main tradenames from several countries containing Reserpine in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An alkaloid found in the roots of Rauwolfia serpentina or Rauwolfia vomitoria, a shrub which is native to India, withdrawal or restricted from the market in Spain (MSC 2004).
Reserpine was the first antihypertensive ever used, nowadays superseded by new products with fewer side effects. It has centrally-acting antidrenergic effects. It can cause sedation and hypotonia.
It has been used to treat hypertension and in psychosis.
Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
There are unconfirmed out-of-date reports that state it is excreted in breastmilk (Nice 2004, White 1984).
Its pharmacokinetic data - not very high molecular weight, low protein binding and very long half-life (Infomed 2018) - makes transfer to milk possible in amounts that could be significant.
It can produce hyperprolactinemia (Molitch 1992, Camanni 1981, Lee 1976).
This product is very little used at present, with a lack of bibliographic data on its pharmacokinetics.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Malachias 2016, WHO 2002), especially during the neonatal period and in cases of prematurity.